DAISHIN SECURITIES noted on the 13th that it expects strong performance in the second half for CLASSYS. Following the second-quarter earnings announcement, the stock price fell, and the analysis indicated that now is the time to buy. The target price has been revised upward from 74,000 won to 78,000 won, and the investment opinion remains "buy."
Han Song-hyup, a researcher at DAISHIN SECURITIES, analyzed, "This adjustment is a buying opportunity that comes while reaffirming the capacity of the main business and the visibility of leverage."
CLASSYS reported second-quarter revenue of 83.3 billion won and operating profit of 43 billion won. This represents increases of 42% and 38%, respectively, compared to the same period last year. Revenue met market expectations (consensus), but operating profit slightly fell short.
DAISHIN SECURITIES presented an estimated third-quarter revenue for CLASSYS of 361.6 billion won and operating profit of 182.5 billion won. With VoluMERS and Ultraformer MPT receiving the European medical device certification (CE-MDR), European sales are expected to ramp up in the second half.
The microneedle RF device QuadSey, launched domestically in July, is strengthening marketing ahead of its release in the U.S. and Japan in the second half. The increase in the number of device installations and the expansion of approved regions are expected to reverse the trend of consumable sales into growth.